Oculis Holding announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA. Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th. The results showed that 57.2% of patients treated with OCS-01 were inflammation free at Day 15, and 75.5% had absence of ocular pain at Day 4. Oculis initiated the second Phase 3 OPTIMIZE-2 trial with OCS-01 once daily eye drop in late 2023 and topline readout is expected before the end of 2024. The two Phase 3 OPTIMIZE trials are expected to support an NDA submission.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Oculis to Participate at Upcoming April Investor Conferences
- Oculis files $300M mixed securities shelf
- Oculis Holding (NASDAQ:OCS): Riding on Bullish Expectations
- Oculis price target lowered to $35 from $64 at Baird
